Abstract
Resistance to antiretroviral drugs is one of the major pitfalls of combined treatment of HIV infection. Thus, timely identification of drug resistant HIV strains and precise evaluation of the level of resistance to the different antiretroviral drugs are crucial in the management of treated patients. Phenotypic determination of antiretroviral drug resistance evaluates the ability of an HIV strain to replicate in the presence of drug(s). Thus, this assay (either conventional or recombinant) provides a direct estimate of drug susceptibility. However, it is relatively difficult to perform and requires dedicated facilities. Thus, its use is still restricted. Genotypic determination of drug resistance is based upon detection of specific mutations in HIV genes encoding target enzymes or receptors. The assay provides an indirect evidence of drug susceptibility. However, it is easy to perform and does not require dedicated facilities. Thus, it is widely utilized in clinical practice. Its major limitation concerns the complexity of results interpretation which still awaits a general consensus.
Keywords: HIV Resistance, Antiviral Drugs, Phenotypic
Current Drug Metabolism
Title: Assays for Determination of HIV Resistance to Antiviral Drugs
Volume: 5 Issue: 4
Author(s): Fausto Baldanti, Stefania Paolucci, Luca Dossena and Giuseppe Gerna
Affiliation:
Keywords: HIV Resistance, Antiviral Drugs, Phenotypic
Abstract: Resistance to antiretroviral drugs is one of the major pitfalls of combined treatment of HIV infection. Thus, timely identification of drug resistant HIV strains and precise evaluation of the level of resistance to the different antiretroviral drugs are crucial in the management of treated patients. Phenotypic determination of antiretroviral drug resistance evaluates the ability of an HIV strain to replicate in the presence of drug(s). Thus, this assay (either conventional or recombinant) provides a direct estimate of drug susceptibility. However, it is relatively difficult to perform and requires dedicated facilities. Thus, its use is still restricted. Genotypic determination of drug resistance is based upon detection of specific mutations in HIV genes encoding target enzymes or receptors. The assay provides an indirect evidence of drug susceptibility. However, it is easy to perform and does not require dedicated facilities. Thus, it is widely utilized in clinical practice. Its major limitation concerns the complexity of results interpretation which still awaits a general consensus.
Export Options
About this article
Cite this article as:
Baldanti Fausto, Paolucci Stefania, Dossena Luca and Gerna Giuseppe, Assays for Determination of HIV Resistance to Antiviral Drugs, Current Drug Metabolism 2004; 5 (4) . https://dx.doi.org/10.2174/1389200043335496
DOI https://dx.doi.org/10.2174/1389200043335496 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Animal Models of Systemic Sclerosis
Current Pharmaceutical Design Optimisation of DMPK by the Inhaled Route: Challenges and Approaches
Current Drug Metabolism Potential Drug Targets on the HIV-1 Envelope Glycoproteins, gp120 and gp41
Current Pharmaceutical Design Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors
Mini-Reviews in Medicinal Chemistry Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Nonviral Gene Therapy
Current Gene Therapy Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Bacterial Proteases in Disease – Role in Intracellular Survival, Evasion of Coagulation/ Fibrinolysis Innate Defenses, Toxicoses and Viral Infections
Current Pharmaceutical Design Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Brain Inflammation is a Common Feature of HIV-Infected Patients without HIV Encephalitis or Productive Brain Infection
Current HIV Research PPARα/HNF4α Interplay on Diversified Responsive Elements. Relevance in the Regulation of Liver Peroxisomal Fatty Acid Catabolism
Current Drug Metabolism Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacokinetics of 3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), a Dual Acting Mutually Masking Prodrug, and Its Metabolites in Tumor Bearing Mice
Current Drug Delivery Immune Defence Mechanisms: Comparing Upper and Lower Airways in Chronic Airway Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)